Facebook
Twitter
LinkedIn
Forward2024 Seattle Cellular Therapy Summit: Updates and Focus on Accessibility
This CME-accredited activity, 2024 Seattle Cellular Therapy Summit: Updates and Focus on Accessibility, features leading experts who will provide a comprehensive overview of current and emerging strategies for the management of lymphoma, myeloma, acute leukemias, and solid tumors with a focus in the use of cellular therapies. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies and to describe potential future applications of cellular therapy in solid tumors. The activity will use a mix of didactic lectures and case-based discussions to highlight areas of debate between cellular therapy and non-cellular therapy in the treatment of these diseases. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care. The faculty will discuss barriers to using cellular therapy and discuss evidence-based strategies to navigate these barriers to incorporate the new standards of care in managing patients with cancer.
The symposium will augment healthcare providers' foundation of knowledge and clinical competence in several areas:
- Providing a review of existing clinical evidence supporting approved Chimeric Antigen Receptor T-cell (CAR T) therapies in the care of patients with hematologic malignancies
- Describing the role of non-cellular therapies in hematologic malignancies
- Identify challenges to the delivery of cellular therapies and provide a discussion on how such barriers may be addressed
- Discussing novel investigational approaches of cellular therapy in acute myeloid leukemias and solid tumors
Organizing Committee
Conference Director:
Binay Shah, MD, MHA - Binaytara Foundation
Conference Co-Chairs:
Mazyar Shadman, MD, MPH - Fred Hutchinson Cancer Center & University of Washington
Krish Patel, MD - Swedish Cancer Institute
Target Audience
- Hematologists/Medical Oncologists
- Oncology fellows
- Oncology nurses
- NPs/PAs
- Oncology pharmacists
Hotel Information
If you are attending this meeting and need to reserve a hotel room, please reserve your room at the link below to take advantage of the discounted group rate of $263 per night plus applicable taxes and fees:
The deadline to reserve the hotel room is Thursday, July 25, 2024.
Learning Objectives
Upon successful completion of this educational activity, participants will be able to:
- Review indications and outcomes of approved cellular therapies in hematologic malignancies
- Identify emerging cellular therapies in hematologic malignancies and solid tumors
- Identify and manage complications after cellular therapy
- State the financial, physical, and other barriers, review strategies to navigate these factors to optimize the management of patients with cellular therapies
GLOBAL ONCOLOGY PROJECT
Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/
DAY 1 – Friday, August 16, 2024
All times are listed in Pacific Time (PT)
07:00 AM – 08:00 AM Registration, Breakfast, & Exhibits
08:00 AM – 08:05 AM Welcome
08:05 AM – 09:20 AM Session 1: Updates on Approved CAR-T Therapies
Session Chair: Mazyar Shadman, MD
08:05 AM – 08:20 AM Updates in CAR-T Therapy for Lymphoma - Saurabh Dahiya, MD
08:20 AM – 08:35 AM Updates in CAR-T Therapy for Myeloma - Krina Patel, MD
08:35 AM – 08:50 AM Updates in CAR-T Therapy for Leukemia - Joseph Tuscano, MD
08:50 AM – 09:20 AM Panel Discussion
09:20 AM – 09:35 AM Break & Exhibits
09:35 AM – 11:05 AM Session 2: Immunotherapy for Solid Tumors
Session Chair: Kelly Paulson, MD
09:35 AM – 09:50 AM Immunotherapy for Solid Tumors - Future Direction - Lawrence Fong, MD
09:50 AM – 10:05 AM TIL Therapy for Melanoma - Kelly Paulson, MD
10:05 AM – 10:20 AM TCR Therapy for Sarcoma - Elizabeth Loggers, MD, PhD
10:20 AM – 10:35 AM Cellular Immunotherapy for Gynecologic Malignancies - Fernanda Musa, MD
10:35 AM – 10:50 AM Cellular Immunotherapy for Breast Cancer - Jennifer Specht, MD
10:50 AM – 11:05 AM Panel Discussion
11:05 AM – 11:50 AM Non-CME Activity
11:50 AM – 12:50 PM Lunch & Exhibits
12:50 PM – 01:50 PM Session 3: Complications
Session Chairs: Mazyar Shadman, MD & Krish Patel, MD
12:50 PM – 01:05 PM Advances in Prevention and Management of CRS and ICANS - Jordan Gauthier, MD, MSc
01:05 PM – 01:20 PM Prevention and Treatment of Infectious Complications after CAR-T Therapy - Joshua Hill, MD
01:20 PM – 01:35 PM Second Malignancies after CAR-T Therapy - Alexandre Hirayama, MD
01:35 PM – 01:50 PM CAR-T Therapy for Autoimmune Diseases - Krish Patel, MD
01:50 PM – 02:05 PM Break & Exhibits
02:05 PM – 02:50 PM Session 4: Access to Cellular Immunotherapy
Session Chair: Krish Patel, MD
02:05 PM – 02:20 PM Cellular Immunotherapy in the Outpatient Setting - Aravind Ramakrishnan, MD
02:20 PM – 02:35 PM Improving Access to CAR-T Therapy - Marc Hoffman, MD
02:35 PM – 02:50 PM Panel Discussion - Lisa Getzendaner, PA-C, MHS; Julia Parker, ARNP
DAY 2 – Saturday, August 17, 2024
07:00 AM – 08:00 AM Registration, Breakfast, & Exhibits
07:30 AM – 08:00 AM Meet the Experts - Thomas Martin, MD; Krina Patel, MD; Elizabeth Budde, MD, PhD; Sattva Neelapu, MD
08:00 AM – 08:15 AM Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD
08:15 AM – 10:35 AM Session 5: Debates in Myeloma
Session Chairs: Rahul Banerjee, MD; Swathi Namburi, MD; Thomas Martin, MD
What is the Right Sequence of Immunotherapy in Multiple Myeloma?
08:15 AM – 08:20 AM Case Presentation - Vivian Liu, MD
08:20 AM – 08:30 AM Bispecific Antibodies before CAR-T Therapy - Meera Mohan, MD, MS, FACP
08:30 AM – 08:40 AM CAR-T Therapy before Bispecific Antibodies - Saad Usmani, MD, MBA, FACP, FASCO
What is the Best Second Line Treatment Option for Myeloma?
08:40 AM – 08:50 AM Favor CAR-T Therapy for Second Line - Gurbakhash Kaur, MD
08:50 AM – 09:00 AM Favor Non CAR-T Options for Second Line - Rahul Banerjee, MD
Is Immunotherapy an Option for Smoldering Myeloma?
09:00 AM – 09:05 AM Case Presentation - Nico Ruiz Lopez, MD
09:05 AM – 09:15 AM Favor Immunotherapy for Smoldering Myeloma - Yuxin Liu, MD
09:15 AM – 09:25 AM Favor Conventional (Non-Immunotherapy) for Smoldering Myeloma - Louis Williams, MD, MBA
09:25 AM – 09:35 AM Favor No Intervention for Smoldering Myeloma - Samuel Rubinstein, MD
09:35 AM – 09:50 AM Novel Target CAR-T - Swathi Namburi, MD
09:50 AM – 10:35 AM Panel Discussion
10:35 AM – 12:00 PM Session 6: Debates in Lymphoma Part 1
Session Chair: Krish Patel, MD
Should Anti-CD19 Therapies Be Used Before CD19 Targeted Car-T therapy?
10:35 AM – 10:40 AM Case Presentation
10:40 AM – 10:50 AM YES - Mehdi Hamadani, MD
10:50 AM – 11:00 AM NO - Matthew Lunning, DO
What is the Best Treatment Option for Post CD19 CAR-T?
11:00 AM – 11:05 AM Case Presentation: Paolo Lopedote, MD
11:05 AM – 11:15 AM Bispecific Antibodies - Tycel Phillips, MD
11:15 AM – 11:25 AM Other Cellular Therapy Options - Matthew Frank, MD, PhD
Immunotherapy for First Line DLBCL
11:25 AM – 11:35 AM CAR-T as the Best Immunotherapy Option for First Line - Sattva Neelapu, MD
11:35 AM – 11:45 AM Bispecific Antibodies as Best First-Line Option for First Line - Ryan Lynch, MD
11:45 AM – 12:00 PM Panel Discussion
12:00 PM – 01:00 PM Lunch & Exhibits
01:00 PM – 03:00 PM Session 7: Debates in Lymphoma Part 2
Session Chair: Alexey Danilov, MD, PhD
Treatment Strategy for CLL Patients With “Double Refractory” Disease
01:00 PM – 01:05 PM Case Presentation - Laura Samples, MD
01:05 PM – 01:15 PM CAR-T (Liso-Cel) - Nirav Shah, MD
01:15 PM – 01:25 PM Pirtobrutinib - Catherine Coombs, MD
01:25 PM – 01:35 PM Allogeneic Stem Cell Transplant - Mazyar Shadman, MD
With Liso-Cel Approval, Which CAR-T Product is Preferred for MCL?
01:35 PM – 01:45 PM Brexu-Cel - Michael Jain, MD, PhD
01:45 PM – 01:55 PM Liso-Cel - Alexey Danilov, MD, PhD
Which Immunotherapy Option is More Promising for T-cell Lymphoma?
01:55 PM – 02:05 PM CAR-T - Rayne Rouce, MD
02:05 PM – 02:15 PM Antibody-Based Immunotherapy - Christina Poh, MD
02:15 PM – 03:00 PM Panel Discussion
03:00 PM – 03:15 PM Break & Exhibits
03:15 PM – 04:40 PM Session 8: Debates in Leukemia
Session Chair: Filippo Milano, MD, PhD
03:15 PM – 03:30 PM Current State of Cellular Immunotherapy for AML - Monica L. Guzman, PhD
CAR-T Therapy of Choice for ALL
03:30 PM – 03:40 PM Brexu-Cel - Ryan Cassaday, MD
03:40 PM – 03:50 PM Obe-Cel - Nitin Jain, MD
Bispecific Antibodies or CAR-T for Relapsed FL
03:50 PM – 03:55 PM Case Presentation - Blossom Raychaudhuri, MD
03:55 PM – 04:05 PM Favor CAR-T - Paolo Strati, MD
04:05 PM – 04:15 PM Favor Bispecific Antibodies - Elizabeth Budde, MD, PhD
The Most Promising Immunotherapy Option for Richter Transformation
04:15 PM – 04:20 PM Case Presentation: Blossom Raychaudhuri, MD
04:20 PM – 04:30 PM CAR-T - Adam Kittai, MD
04:30 PM – 04:40 PM Bispecific Antibodies - Herbert Eradat, MD
04:40 PM Adjourn
If you are attending this meeting and need to reserve a hotel room, please reserve your room at the link below to take advantage of the discounted group rate of $263 per night plus applicable taxes and fees:
The deadline to reserve the hotel room is Thursday, July 25, 2024.
IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:
All conflict of interest has been identified and mitigated for individuals in control of contents.
PLANNING COMMITTEE DISCLOSURE STATEMENT:
None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.
Binay Shah, MD, MHA
Krish Patel, MD
Mazyar Shadman, MD,MPH
Rahul Banerjee, MD, FACP
Alexey Danilov, MD, PhD
Filippo Milano
Kelly Paulson, MD, PhD
Lihua Budde, M.D., Ph.D.
Ryan Cassaday, MD
Catherine Coombs
Saurabh Dahiya
Alexey Danilov, MD, PhD
Lawrence Fong, MD
Matthew Frank, MD PhD
Jordan Gauthier, MD, MSc
Monica Guzman
Mehdi Hamadani
Joshua Hill, MD
Alexandre Hirayama, MD
Marc Hoffmann, Associate Professor; Director, Lymphoma Program
Michael Jain
Adam Kittai, MD
Yuxin Liu, MD
Elizabeth Loggers, MD, PhD
Ryan Lynch
Meera Mohan, MD, MS
Fernanda Musa, MD MS
Sattva Neelapu, MD
Krish Patel, MD
Kelly Paulson, MD, PhD
Tycel Phillips, MD
Christina Poh, MD
Aravind Ramakrishnan, MD
Rayne Rouce
Samuel Rubinstein
Mazyar Shadman, MD,MPH
Nirav Shah, MD
Jennifer Specht, MD
Paolo Strati, MD
Joseph Tuscano, md
Saad Usmani, Chief of Myeloma Service
Lisa Getzendaner, PA-C, MHS
Vivian Liu
Thomas Martin, MD
Sattva Neelapu, MD
Julia Parker
Blossom Suravi Raychaudhuri, MD
Jorge Ruiz Lopez, MD
Available Credit
- 11.50 ABIM MOC IISuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
- 11.50 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 11.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 11.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 11.50 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 11.50 Contact Hours.
If you are interested in exhibiting at this meeting, please email sponsorships@binayfoundation.org
Price
REGISTRATION FEES
Physicians (non-industry) - $300
Non-physician HCP (non-industry) - $200
Industry representatives - $1250
If your company has purchased an exhibit or sponsorship, please register at the link below to receive the discounted registration fees:
Link to register as an additional rep of a sponsoring company: https://education.
NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:
If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:
- If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
- If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event.
Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.
Attend Only Registration Terms & Conditions:
Employees of companies that have not purchased an exhibit space or are not a sponsor of the conference should refrain from interacting with healthcare provider attendees outside of the main meeting room. This applies to ALL interactions except for asking content-relevant questions to faculty inside the meeting room where the CME-accredited activity occurs. Please do not engage in product promotion activity with any attendees or faculty of the conference.
If your company has not purchased an exhibit space or sponsorship, and you engage in any promotional activity, including but not limited to introducing yourself to healthcare providers as an employee of the company, handing out business cards and product brochures/flyers, setting up visits/appointments, inviting them to promotional talks, etc., we will invoice YOU for the full cost of a premium exhibit table.
If your company has not purchased an exhibit space or sponsorship, please limit your interaction with healthcare providers attending this conference to "hello" only if you know the provider. Failure to comply with this requirement may result in being banned from all future conferences.
Employees of companies who are not exhibiting or sponsoring the conference may not enter the exhibit area. The exhibit area is ONLY for exhibitors and sponsors to engage in sales activity. Many of our conferences have meals in the exhibit hall; if the meal is in the exhibit hall, you will need to make alternative arrangements for your meals as you will not be provided meals by the meeting.
CANCELLATION POLICY
You may cancel your enrollment at any time. Cancellation fees apply as below:
- 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
- No refunds will be issued if registration is canceled after that date.
No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post-tests as well as course evaluations.